Exchange: NYSE·Updated 04:52 PM EST

JNJ News

News
all
press releases
Why Did AAPL, COST, JNJ Stocks Hit 52-Week Highs Today?
Investors rotated toward defensive stocks amid AI-sector uncertainty.
Stocktwits
Why Did AAPL, COST, JNJ Stocks Hit 52-Week Highs Today?
Investors rotated toward defensive stocks amid AI-sector uncertainty.
Stocktwits
More News
At Holdings Channel, we have reviewed the latest batch of the 91 most recent 13F filings for the 09/30/2026 reporting period, and noticed that Johnson & Johnson (Symbol: JNJ) was held by 57 of these funds. When hedge fund managers appear to be thinking alike, we find it is a...
Nasdaq News: Markets
ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline.
Zacks
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Key PointsJohnson & Johnson maintains a massive healthcare presence across both innovative medicines and advanced medical technologies...
Nasdaq News: Markets
Johnson & Johnson reports positive Phase 3 CAPLYTA study data, delivering rapid manic symptom relief for adults with bipolar I disorder.read more...
Benzinga
Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.
Zacks
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.
Zacks
Bayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.
Zacks
J&J's oncology sales surge 16.8% to $22 billion in the first nine months of 2026, fueled by blockbuster drugs and new launches.
Zacks

Advertisement|Remove ads.